Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine

Movement Disorders

Volumn 13, Issue 2, 1998, Pages 242-248

  Gassen, Michael ^b   Gross, Aviva ^b   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NONE

Author keywords

Antioxidants; Apomorphine; Free radicals; Iron chelation; Neuroprotection; Parkinson's disease; PC12 cells

Indexed keywords

APOMORPHINE; ASCORBIC ACID; BROMOCRIPTINE; DEFEROXAMINE MESYLATE; HYDROGEN PEROXIDE; LISURIDE; NEUROTOXIN; OXIDOPAMINE; PERGOLIDE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG POTENCY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; APOMORPHINE; CELL SURVIVAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; LIPID PEROXIDATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDANTS; OXIDOPAMINE; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0031950834     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130208     Document Type: Article

References (27)

1. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991;56:1441-1444.
2. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623.
3. Gotz ME, Kunig G, Riederer P, Youdim MBH. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122.
4. Youdim MBH, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 1991;31:34-40.
5. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
6. Allen DR, Wallis GL, McCay PB. Catechol adrenergic agents enhance hydroxyl radical generation in xanthine oxidase systems containing ferritin: implications for ischemia/reperfusion. Arch Biochem Biophys 1994;315:235-243.
7. Urabe K, Aroca P, Tsukamoto K, et al.. The inherent cytotoxicity of melanin precursors: a revision. Biochem Biophys Acta 1994;1221:272-278.
8. Ben-Shachar D, Riederer P, Youdim MBH. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 1991;57:1609-1614.
9. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993;7:121-128.
10. Gassen M, Glinka Y, Pinchasi B, Youdim MBH. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996;308:219-226.
11. Greene LA, Aletta JM, Rukensiein A, Green SH. PC12 pheocytoma cells, culture, nerve growth factor treatment and experimental exploitation. Methods Enzymol 1987;147:207-216.
12. 2+-induced cytotoxicity in PC12-cells. J Neurochem 1994;63:895-902.
13. Vimard F, Nouvelot A, Duval D. Cytotoxic effects of oxidative stress on neuronal-like pheochromocytoma cells. Biochem Pharmacol 1996;51:1389-1395.
14. Walkinshaw G, Waters CM. Induction of apoptosis in catechol-aminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
15. Froissard P, Duval D. Cytotoxic effects of glutamic acid on PC12 cells. Neurochem Int 1994;24:485-493.
16. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AHV. Complex I inhibitors induce dose dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63:1987-1990.
17. Est'vez AG, Radi R, Barbeito L, Shin JT, Thompson JA, Beckman JS. Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. J Neurochem 1995;65:1543-1550.
18. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 1996;141:32-39.
19. Sam EE, Verbeke N. Free radical scavenging properties of apomorphine enanatiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm Park Dis Dement Sect 1995;10:115-127.
20. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl 1995;46:293-310.
21. Andrew R, Watson DG, Best SA, Midgey H, Wenlong H, Petty RKH. The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem Res 1993;18:1175-1177.
22. Dexter DT, Jenner P, Schapira AHV, Mardsen CD. Alterations in level of iron, ferritin and other trace metals in neurodegenerative disease affecting basal ganglia. Ann Neurol 1992;32:94-100.
23. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
24. Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, Youdim MBH. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. J Clin Psychopharmacol 1995;15:51S-59S.
25. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
26. Bayulkem K, Erisir K, Tuncel A, Bayulkem B. A study on the effect and tolerance of lisuride on Parkinson's disease. Adv Neurol 1996;69:519-530.
27. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60:634-637.